自噬
肝细胞癌
细胞毒性T细胞
癌症研究
索拉非尼
自噬体
细胞凋亡
程序性细胞死亡
化学
细胞生物学
生物
生物化学
体外
作者
Lixia Dong,Li Luo,Zihao Wang,Shan Lian,Mao Wang,Xingyun Wu,Jiawu Fan,Yan Zeng,Sijia Li,Sinan Lv,Yurong Yang,Rong Chen,Enhao Shen,Wenyong Yang,Changlong Li,Kui Wang
标识
DOI:10.1016/j.freeradbiomed.2024.04.242
摘要
Hepatocellular carcinoma (HCC) is a global public health problem with increased morbidity and mortality. Agrimol B, a natural polyphenol, has been proved to be a potential anticancer drug. Our recent report showed a favorable anticancer effect of agrimol B in HCC, however, the mechanism of action remains unclear. Here, we found agrimol B inhibits the growth and proliferation of HCC cells in vitro as well as in an HCC patient-derived xenograft (PDX) model. Notably, agrimol B drives autophagy initiation and blocks autophagosome-lysosome fusion, resulting in autophagosome accumulation and autophagy arrest in HCC cells. Mechanistically, agrimol B downregulates the protein level of NADH:ubiquinone oxidoreductase core subunit S1 (NDUFS1) through caspase 3-mediated degradation, leading to mitochondrial reactive oxygen species (mROS) accumulation and autophagy arrest. NDUFS1 overexpression partially restores mROS overproduction, autophagosome accumulation, and growth inhibition induced by agrimol B, suggesting a cytotoxic role of agrimol B-induced autophagy arrest in HCC cells. Notably, agrimol B significantly enhances the sensitivity of HCC cells to sorafenib in vitro and in vivo. In conclusion, our study uncovers the anticancer mechanism of agrimol B in HCC involving the regulation of oxidative stress and autophagy, and suggests agrimol B as a potential therapeutic drug for HCC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI